BCL-XL expression and mutation in non-Hodgkin's lymphoma.
- Author:
Yuan-Hua LIU
1
;
Christophe LEBOEUF
;
Xiao-Long JIN
;
Jia-Cheng XIAO
;
Anne JANIN
;
Sai-Juan CHEN
;
Wei-Li ZHAO
Author Information
1. State Key Laboratory for Medical Genomics, Shanghai Institute of Hematology, Shanghai Ruijin Hospital, Medical College of Shanghai Jiaotong University, Shanghai 200025, China.
- Publication Type:Journal Article
- MeSH:
Base Sequence;
Humans;
Lymphoma, Follicular;
genetics;
pathology;
Lymphoma, Non-Hodgkin;
genetics;
pathology;
Molecular Sequence Data;
Point Mutation;
bcl-X Protein;
biosynthesis;
genetics
- From:
Journal of Experimental Hematology
2006;14(5):903-907
- CountryChina
- Language:Chinese
-
Abstract:
The study was aimed to investigate the BCL-XL expression and mutation, and its clinical significance in non-Hodgkin's lymphoma. Lymphoma cells were selectively isolated by laser microdissection. BCL-XL expression from lymphoma tissue and microdissected lymphoma cells was measured by using real-time quantitative reverse transcription-polymerase chain reaction. BCL-XL mutation was analyzed by using direct sequencing of PCR products. The results showed that compared to 15 patients with reactive hyperplasia, BCL-XL was overexpressed in follicular lymphoma (n = 30), both in lymphoma tissue (P = 0.0064) and in microdissected lymphoma cells (P < 0.0001). No significant rise of BCL-XL expression was observed in patients with T-cell lymphoma (n = 24) and diffuse large B cell lymphoma (n = 24). In follicular lymphoma, high BCL-XL level was associated with multiple extranodal involvement (P = 0.0004), elevated lactate dehydrogenase level (P = 0.0019), high-risk international prognostic index (P = 0.0013) and a short overall survival time (P = 0.0451). Mutation analysis revealed one synonymous mutation (Codon 109 ACA-->ACC) in one case of follicular lymphoma patient. It is concluded that BCL-XL expression is closely correlated with progress of follicular lymphoma and prognosis of patients with follicular lymphoma. The value of BCL-XL expression as a prognostic marker in follicular lymphoma should be considered.
